{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:05:47Z","timestamp":1790651147227,"version":"4.1.0"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2024,10,14]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To estimate real world vaccine effectiveness against symptomatic disease and hospital admission with the delta and omicron variants of the SARS-CoV-2 virus in pregnant individuals, and to estimate the protection conferred by previous infection and maternal vaccination in their infants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Test negative case-control study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Community and hospital testing for covid-19, in England, 26 April 2021 to 9 January 2022 (delta variant period) and 29 November 2021 to 31 March 2022 (omicron variant period). Testing data were linked to Hospital Episode Statistics and Maternal Services Data Set (for data on pregnant individuals and infants), National Immunisation Management System (for covid-19 vaccinations), and Secondary Uses Service (for hospital admissions).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>35\u2009206 negative and 16\u2009693 positive eligible test results in the delta variant period from pregnant individuals with symptoms of infection, aged 16-55 years, whose pregnancy ended in 2021, and 5974 negative and 4715 positive eligible test results in the omicron variant period. For infants born in 2021, 23\u2009053 negative and 2924 positive eligible test results in the delta variant period and 13\u2009908 negative and 5669 positive test results from infants in the omicron period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>Vaccine effectiveness against symptomatic disease and hospital admission with the delta and omicron variants of the SARS-CoV-2 virus in pregnant women. Also, effectiveness of maternal vaccination and the protection conferred by previous infection in mothers in preventing symptomatic disease and hospital admission in their infants in the first six months of life. Symptomatic SARS-CoV-2 infection was confirmed by a positive polymerase chain reaction test result.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Vaccine effectiveness against symptomatic disease (delta and omicron infection) and against hospital admission (delta infection only) in pregnant individuals was high, as seen in the general population. A booster dose of vaccine gave sustained protection, with no evidence of waning up to 15 weeks after vaccination. Vaccine effectiveness against symptomatic disease peaked at 98.4% (95% confidence interval (CI) 88.4% to 99.8%) and 80.1% (73.8% to 84.9%) against the delta and omicron variants, respectively, after the booster dose of vaccine. Vaccine effectiveness after a two dose primary schedule against hospital admission with delta infection peaked at 92.7% (95% CI 79.9% to 97.4%) in pregnant individuals. Maternal vaccination during and after pregnancy also provided sustained protection from symptomatic disease and hospital admission after delta and omicron infection in infants aged up to six months, with the highest protection seen when maternal vaccination occurred during later pregnancy. The effectiveness of two maternal doses when the last dose was given in the third trimester was 86.5% (95% CI 81.9% to 90.0%) and 56.6% (46.7% to 64.6%) against symptomatic disease with delta and omicron infection, respectively, in infants, and effectiveness against hospital admission was 94.7% (78.2% to 98.7%) and 78.7% (58.2% to 89.1%), respectively. Previous infection with wild-type, alpha, and delta variants of the SARS-CoV-2 virus in pregnant individuals was more protective against mild and severe delta infection than omicron infection in their infants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results of this study indicated that maternal vaccination prevented mild and severe disease in pregnant individuals and their infants for up to six months after birth. The findings support the promotion of both primary and booster vaccination for pregnant individuals to protect themselves and their infants.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjmed-2023-000696","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:20:36Z","timestamp":1733530836000},"page":"e000696","source":"Crossref","is-referenced-by-count":7,"title":["Vaccine effectiveness against mild and severe covid-19 in pregnant individuals and their infants in England: test negative case-control study"],"prefix":"10.1136","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-319X","authenticated-orcid":false,"given":"Freja C M","family":"Kirsebom","sequence":"first","affiliation":[{"name":"Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[{"name":"Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, London, UK"},{"name":"London School of Hygiene and Tropical Medicine, National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3291-3416","authenticated-orcid":false,"given":"Anna A","family":"Mensah","sequence":"additional","affiliation":[{"name":"Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Stowe","sequence":"additional","affiliation":[{"name":"Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamez","family":"Ladhani","sequence":"additional","affiliation":[{"name":"Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, London, UK"},{"name":"St George\u2019s University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Ramsay","sequence":"additional","affiliation":[{"name":"Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, London, UK"},{"name":"London School of Hygiene and Tropical Medicine, National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Lopez Bernal","sequence":"additional","affiliation":[{"name":"Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, London, UK"},{"name":"London School of Hygiene and Tropical Medicine, National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London, UK"},{"name":"Imperial College London, National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Respiratory Infections, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-8917","authenticated-orcid":false,"given":"Helen Julia","family":"Campbell","sequence":"additional","affiliation":[{"name":"Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"2025080501031539000_3.1.e000696.1","doi-asserted-by":"crossref","unstructured":"Lindsay L , Calvert C , Shi T , et al . Baby and maternal outcomes following SARS-CoV-2 infection and covid-19 vaccination during pregnancy: a national population-based matched cohort study. SSRN [Preprint] 2023. doi:10.2139\/ssrn.4322399","DOI":"10.2139\/ssrn.4322399"},{"key":"2025080501031539000_3.1.e000696.2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/AOG.0000000000005100","article-title":"Coronavirus Disease 2019 (COVID-19) Vaccination in Pregnancy","volume":"141","author":"Prabhu","year":"2023","journal-title":"Obstet Gynecol"},{"key":"2025080501031539000_3.1.e000696.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m3320","article-title":"Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis","volume":"370","author":"Allotey","year":"2020","journal-title":"BMJ"},{"key":"2025080501031539000_3.1.e000696.4","doi-asserted-by":"crossref","DOI":"10.3390\/healthcare10020203","article-title":"Adverse Perinatal Outcomes in COVID-19 Infected Pregnant Women: A Systematic Review and Meta-Analysis","volume":"10","author":"Pathirathna","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"2025080501031539000_3.1.e000696.5","doi-asserted-by":"crossref","DOI":"10.1080\/01443615.2022.2162867","article-title":"Evaluation of pregnancy outcomes in mothers with COVID-19 infection: a systematic review and meta-analysis","volume":"43","author":"Simbar","year":"2023","journal-title":"J Obstet Gynaecol"},{"key":"2025080501031539000_3.1.e000696.6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.20456","article-title":"Characteristics and Outcomes of Women With COVID-19 Giving Birth at US Academic Centers During the COVID-19 Pandemic","volume":"4","author":"Chinn","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025080501031539000_3.1.e000696.7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.53590","article-title":"Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US","volume":"6","author":"Flaxman","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025080501031539000_3.1.e000696.8","unstructured":"Joint Committee on Vaccination and Immunisation . JCVI issues new advice on COVID-19 vaccination for pregnant women. 2021. Available: https:\/\/www.gov.uk\/government\/news\/jcvi-issues-new-advice-on-covid-19-vaccination-for-pregnant-women"},{"key":"2025080501031539000_3.1.e000696.9","unstructured":"Department of Health & Social Care . Pregnant women urged to come forward for COVID-19 vaccination. 2021. Available: https:\/\/www.gov.uk\/government\/news\/pregnant-women-urged-to-come-forward-for-covid-19-vaccination"},{"key":"2025080501031539000_3.1.e000696.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34605-x","article-title":"Effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy: a national observational study in Israel","volume":"13","author":"Guedalia","year":"2022","journal-title":"Nat Commun"},{"key":"2025080501031539000_3.1.e000696.11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.33273","article-title":"Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States","volume":"5","author":"Schrag","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025080501031539000_3.1.e000696.12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(22)02467-9","article-title":"Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study","volume":"401","author":"Villar","year":"2023","journal-title":"Lancet"},{"key":"2025080501031539000_3.1.e000696.13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijid.2023.01.018","article-title":"The dose- and time-dependent effectiveness and safety associated with COVID-19 vaccination during pregnancy: a systematic review and meta-analysis","volume":"128","author":"Wu","year":"2023","journal-title":"Int J Infect Dis"},{"key":"2025080501031539000_3.1.e000696.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12884-023-05374-2","article-title":"COVID-19 vaccination during pregnancy: a systematic review and meta-analysis","volume":"23","author":"Shafiee","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"key":"2025080501031539000_3.1.e000696.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30052-w","article-title":"Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy","volume":"13","author":"Prasad","year":"2022","journal-title":"Nat Commun"},{"key":"2025080501031539000_3.1.e000696.16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamapediatrics.2022.0001","article-title":"Association of BNT162b2 COVID-19 Vaccination During Pregnancy With Neonatal and Early Infant Outcomes","volume":"176","author":"Goldshtein","year":"2022","journal-title":"JAMA Pediatr"},{"key":"2025080501031539000_3.1.e000696.17","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1044031","article-title":"Associations of COVID-19 vaccination during pregnancy with adverse neonatal and maternal outcomes: A systematic review and meta-analysis","volume":"11","author":"Ding","year":"2023","journal-title":"Front Public Health"},{"key":"2025080501031539000_3.1.e000696.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7563"},{"key":"2025080501031539000_3.1.e000696.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204399"},{"key":"2025080501031539000_3.1.e000696.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074035","article-title":"Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study","volume":"380","author":"Jorgensen","year":"2023","journal-title":"BMJ"},{"key":"2025080501031539000_3.1.e000696.21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamainternmed.2022.2442","article-title":"Association of COVID-19 Vaccination During Pregnancy With Incidence of SARS-CoV-2 Infection in Infants","volume":"182","author":"Carlsen","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2025080501031539000_3.1.e000696.22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jpeds.2022.09.059","article-title":"Effectiveness of BNT162b2 Vaccination During Pregnancy in Preventing Hospitalization for Severe Acute Respiratory Syndrome Coronavirus 2 in Infants","volume":"254","author":"Danino","year":"2023","journal-title":"J Pediatr"},{"key":"2025080501031539000_3.1.e000696.23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2119451"},{"key":"2025080501031539000_3.1.e000696.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00309-7"},{"key":"2025080501031539000_3.1.e000696.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891"},{"key":"2025080501031539000_3.1.e000696.26","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33378-7","article-title":"Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study","volume":"13","author":"Stowe","year":"2022","journal-title":"Nat Commun"},{"key":"2025080501031539000_3.1.e000696.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2022.100537","article-title":"Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England","volume":"23","author":"M\u00f8ller Kirsebom","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2025080501031539000_3.1.e000696.28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(22)00729-0","article-title":"Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021\u2013March, 2022: a national, observational, test-negative, case-control study","volume":"23","author":"Powell","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025080501031539000_3.1.e000696.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2115481"},{"key":"2025080501031539000_3.1.e000696.30","unstructured":"UK Health Security Agency . COVID-19 vaccine surveillance report: week 11. 2022. Available: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1061532\/Vaccine_surveillance_report_-_week_11.pdf"},{"key":"2025080501031539000_3.1.e000696.31","article-title":"Comparing the human milk antibody response after vaccination with four COVID-19 vaccines: A prospective, longitudinal cohort study in the Netherlands","volume":"47","author":"Juncker","year":"2022","journal-title":"EClinMed"},{"key":"2025080501031539000_3.1.e000696.32","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1089\/bfm.2022.0019","article-title":"Comparative Profiles of SARS-CoV-2 Spike-Specific Human Milk Antibodies Elicited by mRNA- and Adenovirus-Based COVID-19 Vaccines","volume":"17","author":"Yang","year":"2022","journal-title":"Breastfeed Med"},{"key":"2025080501031539000_3.1.e000696.33","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1016\/S2666-5247(22)00036-2","article-title":"SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study","volume":"3","author":"Guo","year":"2022","journal-title":"Lancet Microbe"},{"key":"2025080501031539000_3.1.e000696.34","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn4947","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa","volume":"376","author":"Pulliam","year":"2022","journal-title":"Science"},{"key":"2025080501031539000_3.1.e000696.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00365-1"},{"key":"2025080501031539000_3.1.e000696.36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35168-7","article-title":"Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England","volume":"13","author":"Kirsebom","year":"2022","journal-title":"Nat Commun"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2023-000696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T08:03:25Z","timestamp":1754381005000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2023-000696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,5]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bmjmed-2023-000696"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2023-000696","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}